adeno-associated viral vector based aspartoacylase gene therapy (Alzheimer’s disease)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug Nameadeno-associated viral vector based aspartoacylase gene therapy (Alzheimer’s disease)
Drug Alias Namegene therapeutic (Asklepios)AAV2-ASPA gene therapy (Asklepios)
ClassificationBiologics
Mechanisms of ActionNeuroprotectants
TargetsUpdating
Therapy Area/IndicationsAlzheimer Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesAskBio Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAskBio Inc
Active IndicationsN/A
Inactive IndicationsAlzheimer Disease

Other Information

ATC CodeN/A
Related LinksN/A